La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Avanos Medical Crescita futura
Future criteri di controllo 0/6
Avanos Medical is forecast to grow revenue at 4.6% per annum.
Informazioni chiave
n/a
Tasso di crescita degli utili
n/a
Tasso di crescita dell'EPS
| Medical Equipment crescita degli utili | 17.4% |
| Tasso di crescita dei ricavi | 4.6% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Low |
| Ultimo aggiornamento | 01 Aug 2024 |
Aggiornamenti recenti sulla crescita futura
Recent updates
There May Be Some Bright Spots In Avanos Medical's (NYSE:AVNS) Earnings
Aug 07
Lacklustre Performance Is Driving Avanos Medical, Inc.'s (NYSE:AVNS) Low P/S
Apr 17Is Avanos Medical (NYSE:AVNS) A Risky Investment?
Jan 05Some Avanos Medical, Inc. (NYSE:AVNS) Analysts Just Made A Major Cut To Next Year's Estimates
Aug 14When Should You Buy Avanos Medical, Inc. (NYSE:AVNS)?
Aug 13Avanos Medical: Leaning Up, Attractive Returns On Incremental Capital, Reiterate Buy
Jul 16We Think Avanos Medical (NYSE:AVNS) Can Manage Its Debt With Ease
Jun 05Avanos Medical, Inc. (NYSE:AVNS) Stocks Pounded By 26% But Not Lagging Market On Growth Or Pricing
May 18Avanos Medical (NYSE:AVNS) Is Looking To Continue Growing Its Returns On Capital
May 07Is Avanos Medical (NYSE:AVNS) Using Too Much Debt?
Mar 02Avanos Medical Q4 2022 Earnings Preview
Feb 20Avanos Medical, Inc. (NYSE:AVNS) Shares Could Be 30% Below Their Intrinsic Value Estimate
Feb 10Why Avanos Medical, Inc. (NYSE:AVNS) Could Be Worth Watching
Jan 13Avanos Medical reports Q3 mixed earnings; reaffirms FY22 guidance
Nov 02Avanos: Recent Entry To Hyaluronic Acid Market Sparks Interesting Debate
Sep 12Avanos Medical Q2 2022 Earnings Preview
Aug 08When Should You Buy Avanos Medical, Inc. (NYSE:AVNS)?
May 28Is Avanos Medical (NYSE:AVNS) Using Too Much Debt?
May 03Is There An Opportunity With Avanos Medical, Inc.'s (NYSE:AVNS) 41% Undervaluation?
Feb 10Should You Think About Buying Avanos Medical, Inc. (NYSE:AVNS) Now?
Dec 21An Intrinsic Calculation For Avanos Medical, Inc. (NYSE:AVNS) Suggests It's 33% Undervalued
Nov 04Avanos Medical (NYSE:AVNS) Takes On Some Risk With Its Use Of Debt
Sep 10The Strong Earnings Posted By Avanos Medical (NYSE:AVNS) Are A Good Indication Of The Strength Of The Business
Aug 10Is There Now An Opportunity In Avanos Medical, Inc. (NYSE:AVNS)?
Jun 30We Think Avanos Medical (NYSE:AVNS) Is Taking Some Risk With Its Debt
Jun 09Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2026 | 765 | N/A | N/A | N/A | 1 |
| 12/31/2025 | 730 | N/A | N/A | N/A | 3 |
| 12/31/2024 | 695 | N/A | N/A | N/A | 3 |
| 6/30/2024 | 682 | 7 | 42 | 62 | N/A |
| 3/31/2024 | 680 | -2 | 13 | 31 | N/A |
| 12/31/2023 | 673 | -10 | 15 | 32 | N/A |
| 9/30/2023 | 682 | -11 | 37 | 53 | N/A |
| 6/30/2023 | 683 | 9 | 35 | 53 | N/A |
| 3/31/2023 | 684 | 18 | 64 | 82 | N/A |
| 12/31/2022 | 684 | 22 | 72 | 91 | N/A |
| 9/30/2022 | 696 | 23 | 90 | 109 | N/A |
| 6/30/2022 | 708 | -23 | 86 | 104 | N/A |
| 3/31/2022 | 723 | 10 | 72 | 92 | N/A |
| 12/31/2021 | 587 | -31 | 66 | 87 | N/A |
| 9/30/2021 | 736 | -52 | 15 | 36 | N/A |
| 6/30/2021 | 738 | 2 | -5 | 14 | N/A |
| 3/31/2021 | 715 | -38 | -21 | N/A | N/A |
| 12/31/2020 | 715 | -29 | -23 | -2 | N/A |
| 9/30/2020 | 720 | 14 | -30 | -6 | N/A |
| 6/30/2020 | 705 | -17 | -51 | -24 | N/A |
| 3/31/2020 | 714 | -22 | -100 | -57 | N/A |
| 12/31/2019 | 698 | -46 | -125 | -74 | N/A |
| 9/30/2019 | 678 | -42 | -139 | -79 | N/A |
| 6/30/2019 | 671 | -27 | -194 | -130 | N/A |
| 3/31/2019 | 660 | -17 | -247 | -195 | N/A |
| 12/31/2018 | 652 | -8 | -195 | -146 | N/A |
| 9/30/2018 | 649 | -1 | -118 | -74 | N/A |
| 6/30/2018 | 634 | -16 | -30 | 17 | N/A |
| 3/31/2018 | 622 | -28 | N/A | 134 | N/A |
| 12/31/2017 | 612 | -32 | N/A | 144 | N/A |
| 9/30/2017 | -171 | -150 | N/A | 125 | N/A |
| 6/30/2017 | 76 | -130 | N/A | 152 | N/A |
| 3/31/2017 | 327 | -112 | N/A | 183 | N/A |
| 12/31/2016 | 566 | -83 | N/A | 189 | N/A |
| 9/30/2016 | 1,584 | 44 | N/A | 167 | N/A |
| 6/30/2016 | 1,576 | -435 | N/A | 136 | N/A |
| 3/31/2016 | 1,565 | -434 | N/A | 100 | N/A |
| 12/31/2015 | 509 | -101 | N/A | 98 | N/A |
| 9/30/2015 | 1,612 | -443 | N/A | 115 | N/A |
| 6/30/2015 | 1,631 | 20 | N/A | 120 | N/A |
| 3/31/2015 | 1,656 | 7 | N/A | 162 | N/A |
| 12/31/2014 | 1,672 | 27 | N/A | 148 | N/A |
| 9/30/2014 | 1,664 | 69 | N/A | 184 | N/A |
| 6/30/2014 | 1,675 | 125 | N/A | 222 | N/A |
| 3/31/2014 | 1,677 | 168 | N/A | 210 | N/A |
| 12/31/2013 | 1,678 | 155 | N/A | 224 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Insufficient data to determine if AVNS's forecast earnings growth is above the savings rate (2.5%).
Guadagni vs Mercato: Insufficient data to determine if AVNS's earnings are forecast to grow faster than the US market
Guadagni ad alta crescita: Insufficient data to determine if AVNS's earnings are expected to grow significantly over the next 3 years.
Ricavi vs Mercato: AVNS's revenue (4.6% per year) is forecast to grow slower than the US market (8.8% per year).
Ricavi ad alta crescita: AVNS's revenue (4.6% per year) is forecast to grow slower than 20% per year.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Insufficient data to determine if AVNS's Return on Equity is forecast to be high in 3 years time